VIVUS Wraps Up Pivotal Year

VIVUS Wraps Up Pivotal Year
The company's erectile dysfunction medication Stendra earned FDA approval in late April. But Stendra's good news was slightly preceded by the first of Qsymia's many snags. Qsymia originally ran ahead of Arena's Belviq in the approval process and would …

Full News here – Read more on DailyFinance

Leave a Reply